Top 5 Stock Picks of Efrem Kamen’s Pura Vida Investments

3. ViewRay Inc. (NASDAQ:VRAY)

Pura Vida Investments’ Stake Value: $53.2M

Percentage of Pura Vida Investments’ 13F Portfolio: 1.8%

Number of Hedge Fund Holdings: 26

Based out of Cleveland, Ohio, ViewRay Inc. (NASDAQ:VRAY) is a medical technology company which specializes in the production, manufacture and development of FDA-cleared and CE-marked radiation therapy equipment, namely the MRI-Guided Radiation Therapy System, for the effective treatment of cancer. ViewRay Inc. (NASDAQ:VRAY) went public in 2018 and as of the first quarter of 2022, Efrem Kamen’s Pura Vida Investments is the second-largest shareholder of the stock, owning more than 13.6 million shares worth around $53.2 million. A result of Kamen decreasing his hold over the stock by 4%, ViewRay Inc. (NASDAQ:VRAY) now only makes up for 1.8% of Pura Vida’s 13F portfolio.

Investor interest in ViewRay Inc. (NASDAQ:VRAY) seems have to slightly increased in the first quarter of 2022, with 26 hedge funds having stakes in the company, having a cumulative stake value of more than $203.5 million. In the previous quarter, only 23 hedge funds were long the stock, and had a stake worth $270.5 million in ViewRay Inc. (NASDAQ:VRAY). As of Q1 2022, Hudson Executive Capital is the largest shareholder in the stock, having a total stake of $61.7 million.